Gene Mutation Biomarkers for Breast Cancer Diagnostics
Breast cancer remains one of the most prevalent malignancies affecting women worldwide. Gene mutation biomarkers have emerged as crucial components in the diagnostic landscape, allowing for personalized treatment approaches and improved prognostic assessments. At Alfa Cytology, our team of experienced biologists work with you to provide gene mutation biomarker testing for breast cancer diagnostics.
Introduction to Gene Mutation Biomarkers for Breast Cancer
Gene mutations, particularly in key genes such as BRCA1, BRCA2, and TP53, have been extensively studied for their roles in breast cancer susceptibility and progression. The identification of these mutations offers critical information regarding the likelihood of developing breast cancer, as well as potential responses to specific therapies. For example, patients harboring BRCA mutations may benefit from targeted therapies like PARP inhibitors, which exploit the underlying genetic deficiencies in cancer cells.
Fig.1 Tumor and liquid biopsies can help identify gene mutation biomarkers. (Freitas A. J. A. d., et al., 2021)
Recent advancements in next-generation sequencing (NGS) technologies have enhanced the detection of a broader spectrum of genetic alterations. These include single nucleotide variants, insertions, deletions, and copy number variations across various genomic regions. With an emphasis on precision medicine, the characterization of tumor-specific mutations facilitates tailored therapeutic strategies, ultimately improving patient outcomes.
Our Services
At Alfa Cytology, we specialize in the comprehensive analysis of gene mutation biomarkers to facilitate early detection and personalized treatment strategies for breast cancer. Our services include:
Genetic Testing and Analysis
Next-Generation Sequencing
(NGS)
By utilizing NGS, we assess a broad panel of genes, including BRCA1, BRCA2, PIK3CA, and others known to influence breast cancer risk and treatment response.
Liquid
Biopsies
Liquid biopsies offer a non-invasive method of monitoring cancer by analyzing circulating tumor DNA (ctDNA) found in the bloodstream.
Integration of
Artificial Intelligence (AI)
AI algorithms can analyze complex genetic data more efficiently than traditional methods and identifying significant mutations.
Key Gene Mutation Biomarkers
- BRCA1 and BRCA2
- PIK3CA
- TP53
- HER2
- AKT1
- More
For more information about our gene mutation biomarker services and how Alfa Cytology can assist in breast cancer diagnostics, please contact us. Our team of experts is ready to support healthcare providers in navigating the complexities of breast cancer treatment. By leveraging the power of gene mutation biomarkers, Alfa Cytology is dedicated to transforming breast cancer diagnostics and therapy.
References
- Freitas A. J. A. d., Causin R.L., and et al. Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review. Cancers. 2021, 13, 5477.
- Deb S, Chakrabarti A, Fox SB. Prognostic and Predictive Biomarkers in Familial Breast Cancer. Cancers. 2023, 15(4): 1346.